Trevi Therapeutics Inc TRVI:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 1:47 PM EDT
3.73quote price arrow up+0.03 (+0.95%)
Volume
117,850
52 week range
0.46 - 4.68
Loading...
  • Open3.70
  • Day High3.85
  • Day Low3.65
  • Prev Close3.70
  • 52 Week High4.68
  • 52 Week High Date08/09/22
  • 52 Week Low0.46
  • 52 Week Low Date02/23/22

Key Stats

  • Market Cap159.75M
  • Shares Out42.77M
  • 10 Day Average Volume0.38M
  • Dividend-
  • Dividend Yield-
  • Beta0.31
  • YTD % Change379.42

KEY STATS

  • Open3.70
  • Day High3.85
  • Day Low3.65
  • Prev Close3.70
  • 52 Week High4.68
  • 52 Week High Date08/09/22
  • 52 Week Low0.46
  • 52 Week Low Date02/23/22
  • Market Cap159.75M
  • Shares Out42.77M
  • 10 Day Average Volume0.38M
  • Dividend-
  • Dividend Yield-
  • Beta0.31
  • YTD % Change379.42

RATIOS/PROFITABILITY

  • EPS (TTM)-1.34
  • P/E (TTM)-2.78
  • Fwd P/E (NTM)-6.38
  • EBITDA (TTM)-31.364M
  • ROE (TTM)-192.68%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)135.53%

EVENTS

  • Earnings Date11/08/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Trevi Therapeutics Inc

There is no recent news for this security.

Profile

MORE
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio (nalbuphine ER) to treat neurologically mediated conditions. It is engaged in developing Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Haduvio is an oral extended-release (ER) formulation of nalbuphine. It is conducting Phase IIb/3 clinical...
David Meeker M.D.
Chairman of the Board
Jennifer Good
President, Chief Executive Officer, Director
Lisa Delfini CPA
Chief Financial Officer
Address
195 Church St Fl 14
New Haven, CT
06510-2009
United States

Top Peers

SYMBOLLASTCHG%CHG
ACHL
Achilles Therapeutics PLC
3.38+0.02+0.45%
BCLI
Brainstorm Cell Therapeutics Inc
3.68+0.24+6.98%
GLSI
Greenwich Lifesciences Inc
10.00+0.02+0.23%
GALT
Galectin Therapeutics Inc
2.14-0.04-1.83%
AXLA
Axcella Health Inc
2.66-0.07-2.56%